Proteomics International Laboratories Ltd (ASX:PIQ) advises that it is in the closing stages of finalising the detailed terms of its Exclusive Licence Agreement with Sonic Healthcare USA for use of the Company s PromarkerD predictive test for diabetic kidney disease in the United States.
Proteomics International Laboratories (ASX:PIQ) is a medical technology company focused on proteomics – the industrial scale study of the structure and function of proteins. In the last few years, proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems. Proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.